Free tool
FAERS Monitor: Rytelo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217779 or its brand name (Rytelo, Imetelstat Sodium). Reports on generic versions are filed under their own applications.
Reports
186
Serious
103
55% of reports
Hospitalization
36
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- platelet count decreased29
- haemoglobin decreased27
- thrombocytopenia24
- cytopenia20
- neutropenia17
- neutrophil count decreased11
- white blood cell count decreased10
- infusion related reaction9
- death8
- dyspnoea7
- pancytopenia7
- drug ineffective6
- fatigue5
- full blood count decreased5
- intercepted product preparation error5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 41 |
| 2025 | 113 |
| 2026 | 32 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,973 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytopeniaSignal | 20 | 185.0 | 122.2 | 3,475 |
| intercepted product preparation errorSignal | 5 | 46.0 | 19.4 | 177 |
| platelet count decreasedSignal | 29 | 30.8 | 22.0 | 810 |
| neutrophil count decreasedSignal | 11 | 30.5 | 17.2 | 286 |
| haemoglobin decreasedSignal | 27 | 29.7 | 21.0 | 725 |
| full blood count decreasedSignal | 5 | 28.1 | 11.8 | 105 |
| thrombocytopeniaSignal | 24 | 24.3 | 16.7 | 515 |
| infusion related reactionSignal | 9 | 15.4 | 8.1 | 107 |
| pancytopeniaSignal | 7 | 14.2 | 6.8 | 73 |
| neutropeniaSignal | 17 | 14.1 | 9.0 | 196 |
| white blood cell count decreasedSignal | 10 | 10.4 | 5.7 | 77 |
| dyspnoea | 7 | 1.4 | 0.7 | 0 |
| death | 8 | 1.1 | 0.5 | 0 |
| fatigue | 5 | 0.7 | 0.3 | 0 |
| drug ineffective | 6 | 0.5 | 0.2 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.